Hyperprogression after immunotherapy in patients with malignant tumors of digestive system.

PMID:31315610
Ji Z , Peng Z , Gong J , Zhang X , Li J , Lu M , Lu Z , Shen L
BMC cancer
Immune checkpoint inhibitors (ICIs) were approved to have a significant antitumor activity in various tumor types. In practice, some patients do not seem to benefit from ICIs but rather to have accelerating disease. The aim of this study was to evaluate hyperprogression in patients with malignant tumors of digestive system treated with ICIs.


Copyright(C) 2006 BIOIMPACT Co., Ltd. All Rights Reserved